Drugs / Glycosylated Recombinant Human Interleukin-7
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01881867 | Sep 2013 → May 2017 | castration-resistant prostate carcinoma, metastatic prostate carcinoma | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Glycosylated Recombinant Human Interleukin-7 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01881867 ↗ |
| Known as | CYT107 | “Recombinant Glycosylated Human Interleukin-7 (CYT107) After Completion of Standard Therapy” NCT01881867 ↗ |
| Modality | Protein / enzyme biologic | “Biological therapies, such as glycosylated recombinant human interleukin-7, may stimulate the immune system in different ways” NCT01881867 ↗ |
| Route | Subcutaneous | “Given SC” NCT01881867 ↗ |